FATE FY 2013 Earnings — Fate Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

FATEFate Therapeutics, Inc.

$143M

FY 2013 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$971,000-63.6% YoY

Gross Profit

-$11M-1136.6% margin

Operating Income

-$18M-1820.3% margin

Net Income

-$21M-2151.8% margin

EPS (Diluted)

$-1.06

Cash Flow

Operating Cash Flow

-$15M

Free Cash Flow

-$16M

Stock-Based Comp.

$2M

Balance Sheet

Total Assets

$56M

Total Liabilities

$5M

Stockholders' Equity

$51M

Cash & Equivalents

$54M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$971,000	$3M	-63.6%
Gross Profit	-$11M	-$9M	-18.3%
Operating Income	-$18M	-$14M	-30.4%
Net Income	-$21M	-$14M	-46.7%